Genome‐Scale CRISPR‐Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC

Documenti analoghi

• An Integrated Systematic Review and Meta‐Analysis From the Bloodstream to Identify Potential Biomarkers for ALD, MASLD, and HCC Without a Viral Background
  di: Karina González‐García, et al.
  Pubblicazione: (2026)
• Unaddressed Methodological Heterogeneities in the Assessment of HCC Risk After HBsAg Seroclearance
  di: Sen Tao, et al.
  Pubblicazione: (2025)
• Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study
  di: Hwa‐Hee Koh, et al.
  Pubblicazione: (2024)
• Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers
  di: Muhammad Masroor Hussain, et al.
  Pubblicazione: (2026)
• Integrated Multiomics Analysis and Experimental Validation Identify ITPRIPL1 as an Immunoregulatory and Prognostic Biomarker in Gastric Adenocarcinoma
  di: Zixuan Jia, et al.
  Pubblicazione: (2025)